Current stock page

Stock Analysis

Revolution Medicines, Inc. (RVMD) Stock Analysis

Revolution Medicines, Inc. (RVMD) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

RVMD Stock Analysis Summary

Revolution Medicines, Inc. (RVMD) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 73/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

RVMD at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$172.29
AIQ Score55/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$37.03B
P/E Ratio (TTM)-18.83
Forward P/E—
EPS (Q3 FY2026)-$1.90
Revenue (Q3 FY2026)$197.56M
Dividend Yield (TTM)0.00%
Beta1.3
Volume2.65M
52-week range$63.50-$224.31
RSI 1439.68
50-Day SMA$194.46
200-Day SMA$159.88
Analyst Price Target$262.36
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

RVMDRevolution Medicines, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$172.29−$4.06 (−2.30%)

Latest quote

  • Momentum
    73
  • Value
    39
  • Quality
    43
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

RVMD Stock Analysis Summary

Revolution Medicines, Inc. (RVMD) currently has an AIQ Score of 55/100, indicating a neutral setup. Momentum is the strongest factor at 73/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, RVMD has AIQ Score of 55/100 with Momentum base of 73/100 and fading Value at 39/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (73/100) leads while Value (39/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.30% stock move · RVMD classified in Biotechnology.

Current Evidence

NeutralRVMD is in a neutral AIQ regime; Momentum is the strongest visible factor at 73/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is RVMD Bullish or Bearish Right Now?

RVMD currently has a neutral overall setup. Momentum is the strongest factor at 73/100, while Value is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 73/100.
  • - Analyst target implies +52.28% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 39/100.
  • - Technical consensus has more sell votes than buy votes (35 vs 8).

Current Consensus

RVMD's Technical Analysis Consensus is currently Strong Sell, with 8 buy, 3 neutral, and 35 sell votes. RVMD's 14-day RSI is 39.68, which places the stock in a weaker momentum range. RVMD's beta is 1.3, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in RVMD?

The largest recent change in RVMD is Momentum moving down by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-2.0
Momentum
-6.0
Quality
+1.0
Risk
-1.0

What Would Change the RVMD Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

RVMD Decision Framework

Public evidence layers, setup checks, and risk context for Revolution Medicines, Inc..

Revolution Medicines, Inc. (RVMD) Stock Analysis

Revolution Medicines, Inc. has an AIQ Score of 55/100 in a Neutral regime. Momentum is strongest at 73/100. Beta is 1.3, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextRVMD is in a Neutral AIQ regime with score 55/100.
Signal ConflictThe primary conflict is that momentum leads at 73/100 while value lags at 39/100.
Factor EvidenceMomentum 73/100 · Value 39/100 · Quality 43/100 · Risk 59/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 73/100.

TimingPass

Momentum is 73/100 and RSI (14) is 39.7.

Regime fitWait

RVMD is in a Neutral regime at 55/100.

Risk controlWait

Risk factor is 59/100 with beta 1.3 and annual volatility 68.69%.

ConflictWait

Current conflict: momentum leads at 73/100 while value lags at 39/100.

AIQ Score
55/100
Price
$172.29
Beta
1.3
RSI (14)
39.7

RVMD Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

RVMD Fundamentals

RVMD valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$197.56M
Net income
-$407.46M
Free cash flow
-$419.35M
View full RVMD fundamental analysis

RVMD Technical Analysis

RVMD technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
39.68
Price vs SMA-50
-11.40%
View full RVMD technical analysis

RVMD Stock Catalysts

Track RVMD earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$262.36
News items
4
View RVMD earnings and stock catalysts

RVMD Dividend Analysis

RVMD dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View RVMD dividend history and analysis

RVMD Financial Data

RVMD revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$197.56M
EPS
-$1.90
Periods
8
View RVMD financials

RVMD Risk Analysis

RVMD volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.3
Risk score
59/100
1Y volatility
68.69%
View RVMD risk analysis

RVMD Stock News

RVMD stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read RVMD stock news

RVMD vs Biotechnology Peers

Current peer cohort: RVMD · RYTM · SEPN · SLS · SMMT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
RVMD
Current stock
55/10039/10073/10059/1001.6968.69%Current
RYTM
Rhythm Pharmaceuticals, Inc.
62/10052/10072/10057/1000.5254.57%RVMD vs RYTM
SEPN
Septerna Inc
69/10055/10087/10052/1001.4369.35%RVMD vs SEPN
SLS
SELLAS Life Sciences Group, Inc.
57/100—55/10032/1002.04109.89%RVMD vs SLS
SMMT
Summit Therapeutics Inc.
47/100—65/10038/100-0.0175.92%RVMD vs SMMT
Pairwise Compare links: RYTM · SEPN · SLS · SMMTRVMD vs RYTMRVMD vs SEPNRVMD vs SLSRVMD vs SMMTCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a RVMD stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for RVMD: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-18.83
As of Nov 13, 2026
Revenue growth
—
Gross margin
95.16%
Current debt / equity
0.27
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$197.56M
Quarter net income
-$407.46M
Quarter free cash flow
-$419.35M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
39.68
MACD
-3.56

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
59/100
Beta
1.3
Annual volatility
68.69%
Max drawdown
-24.95%

RVMD Stock FAQ

What is RVMD stock price today?

Revolution Medicines, Inc.'s current stock price is $172.29. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is RVMD bullish or bearish right now?

RVMD's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is RVMD's market cap?

RVMD's market cap is $37.03B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is RVMD's current P/E ratio?

RVMD's current P/E ratio is -18.83 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is RVMD's RSI?

RVMD's 14-day RSI is 39.68 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is RVMD above its 50-day and 200-day moving averages?

RVMD is -11.40% from its 50-day SMA and 7.76% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is RVMD's next earnings date?

RVMD's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does RVMD pay a dividend?

RVMD's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.